Search results
Current Drug Targets aims to cover developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. receptors, enzymes, genes.
Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes.
Read the latest articles of Current Cancer Drug Targets at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature.
Current Cancer Drug Targets publishes original research articles, letters/commentary/perspectives, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer.
Feb 20, 2024 · According to the official website of China’s National Medicines and Pharmaceutical Administration (NMPA), a total of 87 novel drugs were approved in China in 2023, with targeted drugs accounting...
May 3, 2023 · Here, we focus on the 12 drugs approved in 2022 with novel MoA targets (Table 1). These targets have not been modulated by any previously approved drug.
Mar 31, 2022 · In 2021, regulatory agencies in the United States, European Union and Japan licensed 59 novel drugs in total, of which 50 have well-established mechanism-of-action (MoA) targets for their...
Jul 17, 2021 · Current guideline recommended drugs classes are represented in bold red; drug classes with existing evidence on an outcome benefit in heart failure are represented in bold blue; novel possible targets are represented in green.
Dec 23, 2021 · A recent development of new therapeutic agents and novel drug targets for cancer treatment - PMC. Journal List. SAGE Open Med. v.9; 2021. PMC8725032. As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health.
More recently, Rask-Andersen et al. 11 provided an updated view on the status of current drugs and the human targets believed to be responsible for their efficacy in their approved indications.
